Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units

Journal of Microbiology, Immunology and Infection

Volumn 51, Issue 6, 2018, Pages 697-704

  Yeh, Ching Yuan ^a   Wang, Fu Der ^b,c   Chuang, Yu Chung ^a   Yang, Chia Jui ^d   Huang, Shiang Fen ^b,c   Weng, Wen Sung ^b   Liaw, Chun Hsin ^d   Sheng, Wang Huei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Critical illness; Influenza; Intravenous peramivir; Pneumonia; Steroid

Indexed keywords

AMINOTRANSFERASE; METHYLPREDNISOLONE; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; STEROID;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BACTEREMIA; CLINICAL OUTCOME; COMORBIDITY; CONTROLLED STUDY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFLUENZA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPTIC SHOCK; SIDE EFFECT; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; INFANT; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TAIWAN; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPENTANES; FEMALE; GUANIDINES; HUMANS; INFANT; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEROIDS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85023633825     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2017.06.001     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. www.cdc.gov/flu/index.htm. [Accessed 7 January 2016].
2. World Health Organization. Fact sheet on influenza. www.who.int/mediacentre/factsheets/fs211/en/index.html. [Accessed 7 January 2016].
3. Shrestha, S.S., Swerdlow, D.L., Borse, R.H., Prabhu, V.S., Finelli, L., Atkins, C.Y., Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis 52 (2011), S75–S82.
4. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. [Accessed 7 January 2016].
5. Hurt, A.C., Ernest, J., Deng, Y.M., Iannello, P., Besselaar, T.G., Birch, C., et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antivir Res 83 (2009), 90–93.
6. Dharan, N.J., Gubareva, L.V., Klimov, A.I., Fiore, A.E., Bresee, J.S., Fry, A.M., Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal influenza A (H1N1) infection during the 2007–2008 influenza season in the United States. Clin Infect Dis 50 (2010), 621–622.
7. Yoshino, Y., Seo, K., Koga, I., Kitazawa, T., Ota, Y., Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J 9 (2015), 229–232.
8. Sugaya, N., Kohno, S., Ishibashi, T., Wajima, T., Takahashi, T., Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56 (2012), 369–377.
9. Kohno, S., Yen, M.Y., Cheong, H.J., Hirotsu, N., Ishida, T., Kadota, J., et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55 (2011), 5267–5276.
10. Lee, N., Chan, P.K., Lui, G.C., Wong, B.C., Sin, W.W., Choi, K.W., et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?. J Infect Dis 203 (2011), 1739–1747.
11. Nakauchi, M., Yasui, Y., Miyoshi, T., Minagawa, H., Tanaka, T., Tashiro, M., et al. One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J Virol Methods 171 (2011), 156–162.
12. Bozdogan, H., Model selection and Akaike's Information Criterion (AIC): the general theory and its analytical extensions. Psychometrika 52 (1987), 345–370.
13. Hastie, T., Tibshirani, R., Generalized additive models for medical research. Stat Methods Med Res 4 (1995), 187–196.
14. Nygard, O., Nordrehaug, J.E., Refsum, H., Ueland, P.M., Farstad, M., Vollset, S.E., Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997), 230–236.
15. Sorbello, A., Jones, S.C., Carter, W., Struble, K., Boucher, R., Truffa, M., et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 55 (2012), 1–7.
16. Yoo, J.W., Choi, S.H., Huh, J.W., Lim, C.M., Koh, Y., Hong, S.B., Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza. J Med Virol 87 (2015), 1649–1655.
17. Louie, J.K., Yang, S., Yen, C., Acosta, M., Schechter, R., Uyeki, T.M., Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS One, 7, 2012, e40261.
18. Leung, C.H., Tseng, H.K., Wang, W.S., Chiang, H.T., Wu, A.Y.J., Liu, C.P., Clinical characteristics of children and adults hospitalized for influenza virus infection. J Microbiol Immunol Infect 47 (2014), 518–525.
19. Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J.S., Lim, W.S., Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis 212 (2015), 183–194.
20. Huang, S.F., Fung, C.P., Perng, D.W., Wang, F.D., Effect of corticosteroid and neuraminidase inhibitor on survival in patients with respiratory distress induced by influenza virus. J Microbiol Immunol Infect 50 (2017), 586–594.
21. Ma, H.Y., Wu, J.L., Lu, C.Y., Chen, J.M., Lee, P.I., Chang, L.Y., et al. Risk factors associated with severe influenza virus infections in hospitalized children during the 2013 to 2014 season. J Microbiol Immunol Infect 49 (2016), 387–393.
22. Louie, J.K., Yang, S., Acosta, M., Yen, C., Samuel, M.C., Schechter, R., et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 55:9 (2012), 1198–1204.
23. Yu, H., Feng, Z., Uyeki, T.M., Liao, Q., Zhou, L., Feng, L., et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis 52 (2011), 457–465.
24. Siston, A.M., Rasmussen, S.A., Honein, M.A., Fry, A.M., Seib, K., Callaghan, W.M., et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 303 (2010), 1517–1525.